湖南华纳大药厂股份有限公司自愿披露关于获得药品注册证书的公告

Core Points - The company has received the drug registration certificate for Polyethylene Glycol Sodium Potassium Powder from the National Medical Products Administration, indicating compliance with drug registration requirements [1][3] - The drug is classified as a Class 4 chemical drug and is intended for the treatment of chronic constipation and fecal impaction [2][3] - The approval of this drug enhances the company's product variety and optimizes its product structure, although it is not expected to have a significant impact on the company's short-term performance [3] Drug Information - Drug Name: Polyethylene Glycol Sodium Potassium Powder [1] - Dosage Form: Powder [1] - Composition: Each package contains 13.1250g of Polyethylene Glycol 3350, 0.3507g of Sodium Chloride, 0.0466g of Potassium Chloride, and 0.1785g of Sodium Bicarbonate [1] - Registration Classification: Class 4 chemical drug [1] - Approval Number: National Drug Approval Number H20255590 [1] Company Impact - The acquisition of the drug registration certificate is expected to positively influence the company's product structure [3] - The drug has not been sold prior to this approval, indicating that its market performance remains uncertain and may be influenced by various factors such as policy changes and market competition [3]